Search Within

Michael John Mauro

Formats
  1. Meeting Abstract (188)
  2. Journal Article (67)
  3. Review (8)
  4. Correspondence (4)
  5. Research Letter (3)
  6. Book Section (2)
  7. Editorial (2)
  8. Guidelines (2)
Groups
  1. Adult Leukemia (276)
  2. Center for Hematologic Malignancies (276)
  3. Department of Medicine (276)
  4. Hematologic Malignancies, Division of (276)
  5. Biostatistics Service (10)
  6. Epidemiology and Biostatistics (10)

More Groups

People
  1. Raajit Rampal (12)
  2. Ellin Berman (8)
  3. Eytan Stein (8)
  4. Martin Tallman (7)
  5. Amber King (6)
  6. Andriy Derkach (6)

More People

Years
  1. 2025 (7)
  2. 2024 (17)
  3. 2023 (26)
  4. 2022 (33)
  5. 2021 (21)
  6. 2020 (26)

More Years

Publications
  1. Blood (97)
  2. Clinical Lymphoma, Myeloma and Leukemia (44)
  3. Journal of Clinical Oncology (22)
  4. Haematologica (21)
  5. Leukemia (12)
  6. American Journal of Hematology (8)

More Publications

Publishers
  1. American Society of Hematology (101)
  2. Elsevier Inc. (47)
  3. American Society of Clinical Oncology (22)
  4. Ferrata Storti Foundation (21)
  5. Nature Publishing Group (13)
  6. John Wiley & Sons (8)

More Publishers

Results (276)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • With up to 8 years of therapy, asciminib (ASC) monotherapy demonstrated continued favorable efficacy, safety, and tolerability in patients (pts) with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) without the T315I mutation: Final results from the phase 1 x2101 study
    Meeting Abstract

    Hochhaus, A.; Kim, D. W.; Cortes, J.; Sasaki, K.; Mauro, M.; Hughes, T. P.; Breccia, M.; Talpaz, M.; Minami, H.; Goh, Y. T.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Asciminib (ASC) in combination with Imatinib (IMA), nilotinib (NIL), or dasatinib (DAS) may be a potential treatment (Tx) option in patients (pts) with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase or accelerated phase (Ph + CML-CP/AP): Final results from the asciminib phase 1 study
    Meeting Abstract

    Cortes, J.; Lang, F.; Rea, D.; Hochhaus, A.; Breccia, M.; Goh, Y. T.; Heinrich, M. C.; Hughes, T. P.; Janssen, J. J. W. M.; le Coutre, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Impact of mutations in blood cancer-related genes on clinical outcomes in chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 tyrosine kinase inhibitors ( TKIs) in the Ascembl trial
    Meeting Abstract

    Branford, S.; Hochhaus, A.; Mauro, M.; Minami, Y.; Rea, D.; Freitas, Cmbd; Serrano-Fernandez, P.; Obourn, V.; Bruederle, A.; Espurz, N.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Estimated savings after stopping tyrosine kinase inhibitor treatment among patients with chronic myeloid leukemia
    Journal Article

    Winn, A. N.; Atallah, E.; Cortes, J.; Deininger, M. W. N.; Kota, V.; Larson, R. A.; Moore, J. O.; Mauro, M. J.; Oehler, V. G.; Pinilla-Ibarz, J.; more...
    JAMA Network Open (2023)

    Fulltext@MSK | Save
  • Responses with asciminib continue to deepen over time in patients with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs) in the phase III ASCEMBL study
    Meeting Abstract

    Mauro, M.; Hochhaus, A.; Hughes, T.; Rea, D.; Boquimpani, C.; Minami, Y.; Apperley, J.; Garcia-Gutiérrez, V.; Kapoor, S.; Espurz, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • First-in-human phase I study of ELVN-001, an oral, selective BCR::ABL1 tyrosine kinase inhibitor, in patients with chronic myeloid leukemia who failed prior tyrosine kinase inhibitors
    Meeting Abstract

    Mauro, M.; Lang, F. B.; Kim, D. W.; Heinrich, M.; Sasaki, K.; Lyssikatos, J.; Collins, H.; Hochhaus, A.
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • ASC2ESCALATE: A US, phase II open-label, single-arm, dose-escalation study of asciminib monotherapy in second-line (2L) and first-line (1L) treatment of patients with chronic myeloid leukemia in chronic phase (CML-CP)
    Meeting Abstract

    Atallah, E.; Mauro, M.; Sasaki, K.; Levy, M.; Koller, P.; Yang, D.; Laine, D.; Sabo, J.; Gu, E. N.; Cortes, J.
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Post hoc analysis of patient responses by T315I mutation status from the 3-year update of the optic trial: A dose-optimization study of 3 starting doses of ponatinib
    Meeting Abstract

    Cortes, J.; Deininger, M.; Lomaia, E.; Moiraghi, B.; Sutton, M. U.; Pavlovsky, C.; Chuah, C.; Sacha, T.; Lipton, J. H.; McCloskey, J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Molecular response of ≤10% BCR::ABL1IS is predictive of positive outcomes in patients with treatment-resistant chronic-phase chronic myeloid leukemia (CP-CML) treated with ponatinib from the phase 2 OPTIC trial
    Meeting Abstract

    Apperley, J.; Cortes, J.; Jabbour, E.; Hochhaus, A.; Hughes, T.; Chuah, C.; de Lavallade, H.; Deininger, M.; Lipton, J. H.; Lomaia, E.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE
    Journal Article

    Shah, N. P.; García-Gutiérrez, V.; Jiménez-Velasco, A.; Larson, S. M.; Saussele, S.; Rea, D.; Mahon, F. X.; Levy, M. Y.; Gómez-Casares, M. T.; Mauro, M. J.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save